Celgene bets $7.2B on Receptos autoimmune med; Teva sells off 22 generics to ANI Pharma;

@FiercePharma: Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Why did FDA ban Emcure India plant? Recall of drugs manufactured for Teva may provide a clue. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AZ's Iressa gets back in the game with first-line FDA approval in lung cancer. Report | Follow @CarlyHFierce

> Celgene ($CELG) extended its spate of deals with a $7.2 billion buyout of Receptos ($RCPT) and its autoimmune drug ozanimod, in Phase III testing for ulcerative colitis and multiple sclerosis. Report

> ANI Pharmaceuticals ($ANIP) snapped up 22 generic drugs from Teva Pharmaceuticals ($TEVA) for $25 million. Report

> Sanofi Pasteur rolled out the first shipments of its 2015-2016 influenza shot Fluzone in the U.S. Report

> Greek pharmacists shuttered their stores Wednesday to protest a new bailout deal that would also allow non-pharmacists to open up pharmacies. Report

Medical Device News

@FierceMedDev: Swedish biotech ropes in $11M for automated HIV testing device. FierceDiagnostics item | Follow @FierceMedDev

@VarunSaxena2: ICYMI: India moving closer to implementing price controls on medical devices. Story | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Noninvasive prenatal tests can pinpoint cancer in mothers. Story | Follow @EmilyWFierce

> U.K. researchers develop noninvasive, infrared-based blood glucose monitor, license it to startup. More

> Breakout Dx player Theranos keys into Medicaid with latest deal in managed care. Article

Biotech News

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: $CELG chief Bob Hugin isn't done betting on 'binary' biotech deals--"we're going to go after them at the right time." Report | Follow @JohnCFierce

@DamianFierce: Here's the $CELG + $RCPT release. PR/Story | Follow @DamianFierce

> Takeda hands in its Velcade successor with blockbuster ambitions. More

> Sanofi carves up its org chart to deliver on a $38B pipeline promise. Report

Pharma Marketing News

> J&J chief touts $1B-plus prospects for coming psoriasis med guselkumab. More

> Dr. Reddy's spruces up corporate branding for U.S. marketing assault. Item

> Roche's atezo lines up PD-L1 data for forthcoming battle with Keytruda, Opdivo. Story

> Two agency giants duke it out for GlaxoSmithKline $900M media account. Report

> Programmatic's the latest word for targeting drug pitches to the right docs. Article

Biotech Research News

> Peptide shells provide a targeted cancer drug delivery system. Item

> Caspase-1 molecule highlighted as key player in regulating vascular ischemia. More

> Johns Hopkins team points to a new therapeutic approach to hearing loss. Report

> Penn study confirms a link between male infertility and genetic mutations. Story

> Nonviral gene therapy shrinks brain tumors in rats. Article

Diagnostics News

> Merck invests $6M in microbial diagnostics specialist OpGen. Report

> Qiagen scores FDA approval for lung cancer companion Dx. News

> Xagenic reels in $15M for point-of-care testing system. Story

> Natera joins forces with University College London for lung cancer study. Article

> CombiMatrix coasts toward growth with renewed sales push. Editor's corner

And Finally... A task force recommended investing in counseling and support programs for people at risk of Type 2 diabetes, citing studies showing the preventive effects of proper diet and exercise. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.